REPORT ID 15825

United States Circulating Tumor Cells Market Report 2017

Publish Date
30-Nov-17
Pages
113
Format
Electronic (PDF)

In this report, the United States Circulating Tumor Cells market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Circulating Tumor Cells in these regions, from 2012 to 2022 (forecast).

United States Circulating Tumor Cells market competition by top manufacturers/players, with Circulating Tumor Cells sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Janssen
    Qiagen?Adnagen?
    Acousys Biodevices
    ApoCell
    Advanced Cell Diagnostics
    Fluxion Biosciences
    Biocept
    Fluidigm
    Epic Sciences
    Clearbridge Biomedics
    Cynvenio
    CytoTrack
    ScreenCell
    Creatv Microtech
    Aviva Biosciences
    Greiner Bio-one
    Sysmex
    Ikonisys

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    CTC Enrichment
    CTC Detection
    CTC Analysis
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Prostate Cancer
    Breast Cancer
    Colorectal Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Circulating Tumor Cells Market Report 2017
1 Circulating Tumor Cells Overview
    1.1 Product Overview and Scope of Circulating Tumor Cells
    1.2 Classification of Circulating Tumor Cells by Product Category
        1.2.1 United States Circulating Tumor Cells Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Circulating Tumor Cells Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 CTC Enrichment
        1.2.4 CTC Detection
        1.2.5 CTC Analysis
    1.3 United States Circulating Tumor Cells Market by Application/End Users
        1.3.1 United States Circulating Tumor Cells Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Prostate Cancer
        1.3.3 Breast Cancer
        1.3.4 Colorectal Cancer
        1.3.5 Others
    1.4 United States Circulating Tumor Cells Market by Region
        1.4.1 United States Circulating Tumor Cells Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Circulating Tumor Cells Status and Prospect (2012-2022)
        1.4.3 Southwest Circulating Tumor Cells Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Circulating Tumor Cells Status and Prospect (2012-2022)
        1.4.5 New England Circulating Tumor Cells Status and Prospect (2012-2022)
        1.4.6 The South Circulating Tumor Cells Status and Prospect (2012-2022)
        1.4.7 The Midwest Circulating Tumor Cells Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Circulating Tumor Cells (2012-2022)
        1.5.1 United States Circulating Tumor Cells Sales and Growth Rate (2012-2022)
        1.5.2 United States Circulating Tumor Cells Revenue and Growth Rate (2012-2022)

2 United States Circulating Tumor Cells Market Competition by Players/Suppliers
    2.1 United States Circulating Tumor Cells Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Circulating Tumor Cells Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Circulating Tumor Cells Average Price by Players/Suppliers (2012-2017)
    2.4 United States Circulating Tumor Cells Market Competitive Situation and Trends
        2.4.1 United States Circulating Tumor Cells Market Concentration Rate
        2.4.2 United States Circulating Tumor Cells Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Circulating Tumor Cells Manufacturing Base Distribution, Sales Area, Product Type

3 United States Circulating Tumor Cells Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Circulating Tumor Cells Sales and Market Share by Region (2012-2017)
    3.2 United States Circulating Tumor Cells Revenue and Market Share by Region (2012-2017)
    3.3 United States Circulating Tumor Cells Price by Region (2012-2017)

4 United States Circulating Tumor Cells Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Circulating Tumor Cells Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Circulating Tumor Cells Revenue and Market Share by Type (2012-2017)
    4.3 United States Circulating Tumor Cells Price by Type (2012-2017)
    4.4 United States Circulating Tumor Cells Sales Growth Rate by Type (2012-2017)

5 United States Circulating Tumor Cells Sales (Volume) by Application (2012-2017)
    5.1 United States Circulating Tumor Cells Sales and Market Share by Application (2012-2017)
    5.2 United States Circulating Tumor Cells Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Circulating Tumor Cells Players/Suppliers Profiles and Sales Data
    6.1 Janssen
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Circulating Tumor Cells Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Janssen Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Qiagen?Adnagen?
        6.2.2 Circulating Tumor Cells Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Qiagen?Adnagen? Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Acousys Biodevices
        6.3.2 Circulating Tumor Cells Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Acousys Biodevices Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 ApoCell
        6.4.2 Circulating Tumor Cells Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 ApoCell Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Advanced Cell Diagnostics
        6.5.2 Circulating Tumor Cells Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Advanced Cell Diagnostics Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Fluxion Biosciences
        6.6.2 Circulating Tumor Cells Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Fluxion Biosciences Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Biocept
        6.7.2 Circulating Tumor Cells Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Biocept Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Fluidigm
        6.8.2 Circulating Tumor Cells Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Fluidigm Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Epic Sciences
        6.9.2 Circulating Tumor Cells Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Epic Sciences Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Clearbridge Biomedics
        6.10.2 Circulating Tumor Cells Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Clearbridge Biomedics Circulating Tumor Cells Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Cynvenio
    6.12 CytoTrack
    6.13 ScreenCell
    6.14 Creatv Microtech
    6.15 Aviva Biosciences
    6.16 Greiner Bio-one
    6.17 Sysmex
    6.18 Ikonisys

7 Circulating Tumor Cells Manufacturing Cost Analysis
    7.1 Circulating Tumor Cells Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Circulating Tumor Cells

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Circulating Tumor Cells Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Circulating Tumor Cells Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Circulating Tumor Cells Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Circulating Tumor Cells Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Circulating Tumor Cells Sales Volume Forecast by Type (2017-2022)
    11.3 United States Circulating Tumor Cells Sales Volume Forecast by Application (2017-2022)
    11.4 United States Circulating Tumor Cells Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer